[Strong]-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

kera
2022-12-30

[Strong]

Kala Pharmaceuticals Stock Surges 16% as FDA Accepts Drug Application For Eye Condition

Shares of $Kala Pharmaceuticals Inc.$ shot up 16% in morning trading, after the biopharmaceutical company said the Food and Drug Administration accepted its investigational new drug application for KPI-012, its treatment of persistent corneal epithelial defect .With the acceptance, the company said late Tuesday that it is now turning its focus to clinical execution, and is looking to initiate a Phase 2 trial KPI-012 in the first quarter of 2023.Also with the IND acceptance and under terms of a

Kala Pharmaceuticals Stock Surges 16% as FDA Accepts Drug Application For Eye Condition

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":9927938016,"tweetId":"9927938016","gmtCreate":1672366793936,"gmtModify":1676538679732,"author":{"id":4123326866212482,"idStr":"4123326866212482","authorId":4123326866212482,"authorIdStr":"4123326866212482","name":"kera","avatar":"https://community-static.tradeup.com/news/b76fe0dbe31d67b47f6f33dc7546c589","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p><span>[Strong]&nbsp;</span></p></body></html>","htmlText":"<html><head></head><body><p><span>[Strong]&nbsp;</span></p></body></html>","text":"[Strong]","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/9927938016","repostId":1151980417,"repostType":4,"repost":{"id":"1151980417","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1672326372,"share":"https://www.laohu8.com/m/news/1151980417?lang=&edition=full","pubTime":"2022-12-29 23:06","market":"us","language":"en","title":"Kala Pharmaceuticals Stock Surges 16% as FDA Accepts Drug Application For Eye Condition","url":"https://stock-news.laohu8.com/highlight/detail?id=1151980417","media":"Tiger Newspress","summary":"Shares of $Kala Pharmaceuticals Inc.$  shot up 16% in morning trading, after the biopharmaceutical company said the Food and Drug Administration accepted its investigational new drug  application for KPI-012, its treatment of persistent corneal epithelial defect .With the acceptance, the company said late Tuesday that it is now turning its focus to clinical execution, and is looking to initiate a Phase 2 trial KPI-012 in the first quarter of 2023.Also with the IND acceptance and under terms of a","content":"<html><head></head><body><p>Shares of <a href=\"https://laohu8.com/S/KALA\">Kala Pharmaceuticals Inc.</a> (KALA) shot up 16% in morning trading, after the biopharmaceutical company said the Food and Drug Administration accepted its investigational new drug (IND) application for KPI-012, its treatment of persistent corneal epithelial defect (PCED).</p><p><img src=\"https://static.tigerbbs.com/97d28c24e7ebb80a4277b892b046ea1d\" tg-width=\"792\" tg-height=\"687\" width=\"100%\" height=\"auto\"/>With the acceptance, the company said late Tuesday that it is now turning its focus to clinical execution, and is looking to initiate a Phase 2 trial KPI-012 in the first quarter of 2023.</p><p>Also with the IND acceptance and under terms of a private placement announced last month, the company said it raised $25 million by selling a total of 43,478 shares of Series E convertible preferred stock at $575.00 a share to &#34;a life sciences-focused investor.&#34; Kala&#39;s stock has plummeted 93.5% in 2022, while the <a href=\"https://laohu8.com/S/EMDI\">iShares</a> Biotechnology ETF <a href=\"https://laohu8.com/S/IBB\">$(IBB)$</a> has lost 15.3% and the S&amp;P 500  has declined 19.7%.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kala Pharmaceuticals Stock Surges 16% as FDA Accepts Drug Application For Eye Condition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKala Pharmaceuticals Stock Surges 16% as FDA Accepts Drug Application For Eye Condition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2022-12-29 23:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Shares of <a href=\"https://laohu8.com/S/KALA\">Kala Pharmaceuticals Inc.</a> (KALA) shot up 16% in morning trading, after the biopharmaceutical company said the Food and Drug Administration accepted its investigational new drug (IND) application for KPI-012, its treatment of persistent corneal epithelial defect (PCED).</p><p><img src=\"https://static.tigerbbs.com/97d28c24e7ebb80a4277b892b046ea1d\" tg-width=\"792\" tg-height=\"687\" width=\"100%\" height=\"auto\"/>With the acceptance, the company said late Tuesday that it is now turning its focus to clinical execution, and is looking to initiate a Phase 2 trial KPI-012 in the first quarter of 2023.</p><p>Also with the IND acceptance and under terms of a private placement announced last month, the company said it raised $25 million by selling a total of 43,478 shares of Series E convertible preferred stock at $575.00 a share to &#34;a life sciences-focused investor.&#34; Kala&#39;s stock has plummeted 93.5% in 2022, while the <a href=\"https://laohu8.com/S/EMDI\">iShares</a> Biotechnology ETF <a href=\"https://laohu8.com/S/IBB\">$(IBB)$</a> has lost 15.3% and the S&amp;P 500  has declined 19.7%.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"KALA":"KALA BIO"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151980417","content_text":"Shares of Kala Pharmaceuticals Inc. (KALA) shot up 16% in morning trading, after the biopharmaceutical company said the Food and Drug Administration accepted its investigational new drug (IND) application for KPI-012, its treatment of persistent corneal epithelial defect (PCED).With the acceptance, the company said late Tuesday that it is now turning its focus to clinical execution, and is looking to initiate a Phase 2 trial KPI-012 in the first quarter of 2023.Also with the IND acceptance and under terms of a private placement announced last month, the company said it raised $25 million by selling a total of 43,478 shares of Series E convertible preferred stock at $575.00 a share to \"a life sciences-focused investor.\" Kala's stock has plummeted 93.5% in 2022, while the iShares Biotechnology ETF $(IBB)$ has lost 15.3% and the S&P 500  has declined 19.7%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":241,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":8,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}